Turkey's Social Security Institution (SGK) published Announcement 2026/34 on September 2, 2026, amending the Bedeli Ödenecek İlaçlar Listesi (List of Reimbursable Pharmaceuticals) under Article 12 of the Sağlık Uygulama Tebliği (SUT, Health Implementation Communiqué). The amended list takes effect on September 4, 2026, giving marketing authorisation holders (MAHs) two days to confirm whether their products' reimbursement status was added, removed or repriced.
The announcement, issued by SGK's General Health Insurance General Directorate, carries two attachments: a PDF setting out the Article 12 changes and an XLSX publishing the updated list rows. It is the second consecutive SUT Article 12 list update in under two weeks, after Announcement 2026/33 whose annex applied on August 28, 2026.
What does Announcement 2026/34 change in the reimbursable medicines list?
Article 12 of the SUT is the operative provision that defines which pharmaceuticals SGK reimburses and on what terms. Announcement 2026/34 amends that list, adding, removing and repricing the reimbursement conditions of specific active substances and presentations. The binding instrument is the announcement itself, published on SGK's official duyuru page, with the XLSX attachment giving the row-level detail that pharmacists and reimbursement systems must load.
Because the SUT is classified in Turkish law as a Tebliğ (communiqué) with binding force, an Article 12 announcement is not guidance. It is an operative amendment to the reimbursement list, and pharmacies may not dispense a product at the reimbursed rate against a status the new list has removed.
Which pharmaceutical companies must act, and by when?
The change binds every MAH selling into the Turkish market, domestic and foreign. Domestic manufacturers such as Abdi Ibrahim, Bilim, Nobel and Deva, and foreign MAHs with Turkish authorised representatives such as Pfizer, Novartis, Roche and Sanofi, must each check the new list against their portfolio. The effective date is September 4, 2026, so the review must complete before that date to avoid dispensing or billing against a stale reimbursement status.
Distributors and healthcare compliance teams should treat the XLSX as the control document: any product whose reimbursement percentage, reference price or coverage condition moved in this announcement must be updated in internal pricing and pharmacy IT systems on the day the list applies.
How does the SUT Article 12 list gate market access in Turkey?
Turkey splits medicines regulation across three bodies, and missing that split is the most common error international trackers make. TİTCK grants the marketing authorisation (Ruhsat). The Ministry of Health-coordinated Pricing Evaluation Commission (Fiyat Değerlendirme Komisyonu) sets the price. SGK alone decides reimbursement, through the SUT list and the clinical and pharmacoeconomic evaluation run by its TEDK (Tıbbi ve Ekonomik Değerlendirme Komisyonu) committee.
| Body | Role | Instrument |
|---|---|---|
| TİTCK | Marketing authorisation (Ruhsat) | Law 1262 / 7333 |
| Pricing Evaluation Commission (MoH) | Sets the price | Pricing Decree and Communiqué |
| SGK | Reimbursement list (SUT Article 12) | Sağlık Uygulama Tebliği |
The hard rule is that no SUT listing means no reimbursement, and no reimbursement means no real market access in Turkey. A product can hold a valid Ruhsat and an official price yet still not be reimbursable until SGK lists it under Article 12. Each Article 12 update can therefore move a product from reimbursed to non-reimbursed, or change the percentage SGK pays, which directly resets the commercial economics of a medicine in the Turkish market.
What should MAHs do before September 4, 2026?
MAHs should download the 2026/34 XLSX and diff it against the 2026/33 list for every owned product, confirm the added, removed and repriced reimbursement statuses, update pricing and pharmacy IT systems with the new statuses, and brief the regulatory affairs and market access team on the commercial impact. The review must close before the September 4, 2026 effective date, because pharmacies and SGK billing systems apply the new list from that day.
Continuous, per-jurisdiction real-time monitoring surfaces an Article 12 list change the moment SGK publishes it, which matters when the update cadence runs this tight.
Subscribe to the free newsletter
The source of record is the SGK announcement page and its attachments. Verify each product's reimbursement status there, confirm the effective date with the Turkish authorised representative, and brief the market access team on any product whose coverage or reimbursement percentage changed in this amendment.
